Quantum Genomics and Biolab Sanus Pharmaceutical have entered into an exclusive licensing and collaboration agreement to develop and commercialize firibastat in Latin America. This is the first regional partnership for Quantum Genomics.
Under the terms of the agreement, Biolab Sanus Pharmaceutical will receive exclusive commercialization rights to firibastat for the treatment of arterial hypertension in Latin America. Quantum Genomics will receive upfront and milestone payments amounting up to $21.2 million, plus royalties on sales. Biolab Sanus Pharmaceutical will fund part of the Phase III study in difficult to treat/resistant hypertension in Latin America as part of the overall pivotal Phase III trial led by Quantum Genomics.
"With its portfolio of over 140 products and a strong concentration on hypertension, Biolab Sanus Pharmaceutical is the perfect partner for us in the Latin America market. Its extensive and established cardiology sales force will help to ensure that firibastat, if approved, can transform the standard of care for patients suffering from arterial hypertension throughout Latin America and create long-term shareholder value,” said Jean-Philippe Milon, CEO of Quantum Genomics. “We look forward to include Latin America in our global Phase III trial of firibastat in difficult to treat/resistant hypertension.”
"The Phase IIb results of firibastat in arterial hypertension are highly encouraging. Firibastat’s activity across historically difficult-to-treat populations, such as elderly, obese, black and Hispanic groups, fits well into our existing cardiology portfolio and we are excited to have the opportunity to bring this potentially transformative drug to the Latin American community,” Cleiton de Castro Marques, CEO of Biolab Sanus Pharmaceutical, said.